window.pageData = {"stock":{"_id":3000000011383,"stockCode":"011383","shortName":"富安达医药创新混合A","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","fundCollection":{"exchange":"jjgs","stockType":"fund_collection","stockCode":"50650000","tickerId":50650000,"name":"富安达基金管理有限公司"},"managers":[{"name":"李守峰","stockType":"fund_manager","stockCode":"db20077904","exchange":"fm","tickerId":121906158610}],"hotMetrics":{"fss":{"stockId":3000000011383,"type":"fss","f_s_s_d":"2024-06-29T16:00:00.000Z","f_ins_h_s_r":0.1722,"f_ins_h_s_r_c_hy":0.0169,"f_ins_h_s_r_c_1y":0.026900000000000007,"f_ind_h_s_r":0.8278,"f_ind_h_s_r_c_hy":-0.016900000000000026,"f_ind_h_s_r_c_1y":-0.026900000000000035,"f_h_a":2430,"f_h_s_a":59119,"last_data_date":"2025-12-30T16:00:00.000Z"},"fpr":{"stockId":3000000011383,"type":"fpr","f_p_r_fys_ssc":8947,"f_p_r_fys_ssrp":0.40509725016767273,"f_p_r_m1_ssc":9334,"f_p_r_m1_ssrp":0.04800171434694096,"f_p_r_m3_ssc":9171,"f_p_r_m3_ssrp":0.6079607415485279,"f_p_r_m6_ssc":8947,"f_p_r_m6_ssrp":0.40520903196959535,"f_p_r_y1_ssc":8422,"f_p_r_y1_ssrp":0.7735423346395915,"f_p_r_y2_ssc":7792,"f_p_r_y2_ssrp":0.6497240405596201,"f_p_r_y3_ssc":7007,"f_p_r_y3_ssrp":0.9430488153011705,"f_cagr_p_r_fs_ssc":9328,"f_cagr_p_r_fs_ssrp":0.9571137557628391,"f_p_r_y5_ssc":4529,"f_p_r_y5_ssrp":0.9545053003533569},"fp":{"stockId":3000000011383,"type":"fp","f_p_r_fys":0.09725196288365434,"f_p_r_m1":0.1692336946187485,"f_p_r_m3":0.017372600926538695,"f_p_r_m6":0.09725196288365434,"f_p_r_y1":0.03431455004205186,"f_cagr_p_r_fs":-0.08740789528734016,"f_p_r_d1":0.015109637000184195,"f_p_r_y2":0.2214938418752479,"f_p_r_y3":-0.1665763079425323,"last_data_date":"2026-07-02T16:00:00.000Z","f_p_r_y5":-0.4409491771979266,"f_i_d":"2021-03-08T16:00:00.000Z"},"ff":{"stockId":3000000011383,"type":"ff","f_m_f":631347,"f_m_f_r":0.012,"f_c_f":105224,"f_c_f_r":0.002,"f_m_a_c_f":736571,"f_m_a_c_f_r":0.014,"f_m_c_f_d":"2025-03-05T16:00:00.000Z","f_c_fr":0.002,"f_fr_d":"2026-02-26T16:00:00.000Z","f_m_fr":0.012,"f_mac_fr":0.014},"f_nlacan":{"stockId":3000000011383,"type":"f_nlacan","f_nv_d":"2026-07-02T16:00:00.000Z","f_nv":0.6149,"f_nv_cr":0.023809523809523725},"f_as":{"stockId":3000000011383,"type":"f_as","f_tas":78558023.118,"f_tas_d":"2026-03-30T16:00:00.000Z"}},"masterSlaveFunds":[{"_id":3000000026857,"name":"富安达医药创新混合型证券投资基金","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","status":"normal","stockCode":"026857","tickerId":26857,"shortName":"富安达医药创新混合C","currency":"CNY","__csrcFundId":8785,"exchange":"jj","masterFundFlag":null,"indexFundFlag":null,"activeFundFlag":null,"etfFundFlag":null,"lofFundFlag":null,"pensionTargetFlag":null,"feederFundFlag":null,"classificationFlag":null,"closedEnd":null,"lastUpdated":"2026-03-09T08:01:41.859Z","inceptionDate":"2026-02-26T16:00:00.000Z","pinyin":"fadyycxhhxzqtzjj","fundCollectionId":4000050650000}],"shareholdings":[{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000011383,"stockId":600276,"holdings":87100,"marketCap":4809662,"netValueRatio":0.0612,"quarterlyChange":-0.07302333389289883,"stock":{"stockCode":"600276","exchange":"sh","stockType":"company","tickerId":600276,"name":"恒瑞医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000011383,"stockId":688197,"holdings":111718,"marketCap":4310080,"netValueRatio":0.0548,"quarterlyChange":0.11053540587219368,"stock":{"name":"首药控股","exchange":"sh","stockType":"company","stockCode":"688197","tickerId":688197}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000011383,"stockId":603259,"holdings":42300,"marketCap":4149630,"netValueRatio":0.0528,"quarterlyChange":0.08230361871138547,"stock":{"stockCode":"603259","exchange":"sh","stockType":"company","tickerId":603259,"name":"药明康德"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000011383,"stockId":2422,"holdings":118300,"marketCap":4103827,"netValueRatio":0.0522,"quarterlyChange":0.1819420783645651,"stock":{"stockCode":"002422","exchange":"sz","stockType":"company","tickerId":2422,"name":"科伦药业"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000011383,"stockId":688180,"holdings":112391,"marketCap":3914578,"netValueRatio":0.0498,"quarterlyChange":0.01961358313817363,"stock":{"stockCode":"688180","tickerId":688180,"exchange":"sh","stockType":"company","name":"君实生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000011383,"stockId":688192,"holdings":71451,"marketCap":3871929,"netValueRatio":0.0493,"quarterlyChange":-0.059201388888888706,"stock":{"stockCode":"688192","tickerId":688192,"exchange":"sh","stockType":"company","name":"迪哲医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000011383,"stockId":2755,"holdings":245300,"marketCap":3841398,"netValueRatio":0.0489,"quarterlyChange":-0.041028781383954605,"stock":{"stockCode":"002755","exchange":"sz","stockType":"company","tickerId":2755,"name":"奥赛康"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000011383,"stockId":688443,"holdings":142934,"marketCap":3667686,"netValueRatio":0.0467,"quarterlyChange":-0.05800293685756264,"stock":{"name":"智翔金泰","exchange":"sh","stockType":"company","stockCode":"688443","tickerId":688443}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000011383,"stockId":688293,"holdings":84519,"marketCap":3634317,"netValueRatio":0.0462,"quarterlyChange":-0.12244897959183709,"stock":{"name":"奥浦迈","exchange":"sh","stockType":"company","stockCode":"688293","tickerId":688293}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000011383,"stockId":688506,"holdings":11743,"marketCap":3264554,"netValueRatio":0.0415,"quarterlyChange":-0.13958526771897228,"stock":{"name":"百利天恒","exchange":"sh","stockType":"company","stockCode":"688506","tickerId":688506}}],"lastFsMetrics":{"latestTurnoverRate":7.675929770251095,"latestTurnoverRateDate":"2025-12-30T16:00:00.000Z"}},"list":[{"_id":"69e7d57e6201787ae129f250","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","stockId":3000000011383,"sao":"2026年一季度A股整体震荡下行，上证指数下跌1.94%，深证成指下跌0.35%，创业板指数下跌0.57%；行业间分化，煤炭、石化、建材等板块涨幅较大，非银、商贸零售、美容护理、家电等行业则有一定下跌。本基金主要配置医药行业中创新相关的方向，我们认为创新药仍是2026年医药行业重点投资方向之一，部分创新药个股深度回调后，投资性价比显现。报告期内，我们精选了部分临床数据较好仍有BD潜力的标的进行加仓，除了创新药板块以外，创新药的复苏也有望带动上游CXO板块，我们也增持了这个细分板块，我们还持少量仓位的高分红中药。","lastUpdated":"2026-04-21T19:52:30.969Z","fund":{"_id":3000000011383,"__csrcFundId":8785,"stockCode":"011383","shortName":"富安达医药创新混合(011383)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"lastUpdated":"2026-04-30T22:47:34.569Z","status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","managers":[{"stockCode":"db20077904","stockType":"fund_manager","exchange":"fm","tickerId":121906158610,"name":"李守峰"}]},"announcement":{"linkText":"富安达医药创新混合型证券投资基金2026年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1469618","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69c7701869b11a867413e0d9","date":"2025-12-30T16:00:00.000Z","declarationDate":"2026-03-27T16:00:00.000Z","stockId":3000000011383,"sao":"2025年A股虽然受到贸易战冲击，但整体呈现慢牛格局，上证指数上涨18.41%，深证成指上涨29.87%，创业板指数上涨49.57%，行业间分化明显，有色、通信、电子、等板块涨幅较大，消费类的板块如食品饮料等则有一定下跌。本基金主要配置在医药行业中有创新性较强的方向，回顾2025年全年创新药是唯一主线但持续时间相对较短，8月份即开始见顶调整。我们上半年创新药的配置比例不高，8月创新药见顶以后板块持续调整，而我们认为创新药仍是2026年医药行业重点投资方向之一，因此四季度我们精选了部分临床数据较好仍有BD潜力的个股进行加仓，除了创新药板块以外，我们加仓了受益于创新药复苏的上游CXO板块，另外，我们还持有一定仓位有望业绩反转的医疗器械股。","lastUpdated":"2026-03-28T06:07:20.033Z","mo":"2021年医药行业见顶以来，中证医药指数2021-2024年已经连续四年下跌，2025年医药行业指数开始止跌，中证医药指数微涨4.36%，创新药是全年的唯一主线，主要得益于国内医保支付端政策向好、医保品种放量带来不少上市公司逐渐扭亏、海外BD加速等因素。展望2026年我们认为国内支付端仍面临一定的压力，出海是国内药企突破成长天花板的重要方式，特别是出海相关的创新药和医疗器械板块，随着创新药板块的景气度复苏，上游为其配套的CXO板块景气度有望反转，也是我们密切跟踪的方向之一。","fund":{"_id":3000000011383,"__csrcFundId":8785,"stockCode":"011383","shortName":"富安达医药创新混合(011383)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"lastUpdated":"2026-04-30T22:47:34.569Z","status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","managers":[{"stockCode":"db20077904","stockType":"fund_manager","exchange":"fm","tickerId":121906158610,"name":"李守峰"}]},"announcement":{"linkText":"富安达医药创新混合型证券投资基金2025年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1450169","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aece787fea5b3eb04ebcc0","date":"2025-09-29T16:00:00.000Z","declarationDate":"2025-10-24T16:00:00.000Z","stockId":3000000011383,"sao":"2025年三季度A股震荡上行，上证指数上涨12.73%，深证成指上涨29.25%，创业板指数上涨50.4%；有色、通信、电子、电力设备等板块涨幅较大，交通运输和食品饮料涨幅较小，银行板块下跌幅度较大。本基金主要配置医药行业中医药创新相关的方向，三季度中证医药指数延续二季度的上涨，单季度中证医药卫生指数上涨16.88%，创新药的上游科研服务板块以及CXO相对于行业有显著超额。考虑到年初以来市场预期的BD交易兑现较少，而相当多的创新药的相关标的已经反映了潜在的BD预期，三季度我们降低了部分创新药的持仓，当前主要持仓在以下几个方向：一是与财政政策相关度最大的医疗器械设备行业，医院的需求只会延续不会消失，2025年三季度陆续有公司见到业绩拐点，器械和设备板块有望贡献绝对收益；二是创新药的上游CXO，创新药的高景气有望带动2026年创新药上游景气度的触底回升；三是估值相对合理的创新药及仿创龙头。","lastUpdated":"2026-03-09T13:43:20.409Z","fund":{"_id":3000000011383,"__csrcFundId":8785,"stockCode":"011383","shortName":"富安达医药创新混合(011383)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"lastUpdated":"2026-04-30T22:47:34.569Z","status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","managers":[{"stockCode":"db20077904","stockType":"fund_manager","exchange":"fm","tickerId":121906158610,"name":"李守峰"}]},"announcement":{"linkText":"富安达医药创新混合型证券投资基金2025年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1370683","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aece787fea5b3eb04ebcbf","date":"2025-06-29T16:00:00.000Z","stockId":3000000011383,"sao":"2025年上半年A股韧性较强，虽然受到贸易战的冲击但整体小幅上涨，上证指数上涨2.76%，深证成指微涨0.48%，创业板指数微涨0.53%，行业间分化明显，有色、军工、传媒、医药等板块涨幅较大，煤炭、石化、地产等板块则有一定下跌。本基金主要配置在医药行业，一季度我们重点配置在招标逐渐恢复的医疗设备器械及业绩稳定的中药板块，二季度我们重点布局在具备管线重估价值的部分仿制药、原料药和中成药，上半年整体相对于业绩比较基准取得了一定的超额收益。我们当前主要持仓在以下几个方向：一是与财政政策相关度最大的医疗设备/器械行业，医院的需求只会延续不会消失，2025年二季度或三季度可能陆续有公司见到业绩拐点，部分医疗器械公司同样具备创新属性；二是泛创新方向，具有管线重估价值的传统药企，如部分中药、原料药公司，三是下半年仍有BD预期的部分创新药公司。","declarationDate":"2025-07-18T16:00:00.000Z","lastUpdated":"2026-03-09T13:43:20.407Z","mo":"2021年医药行业见顶以来，中证医药指数2021-2024年已经连续四年下跌，2025年上半年医药行业指数开始止跌，中证医药指数微涨2.27%，创新药是上半年的唯一主线，主要得益于国内医保支付端政策向好、医保品种放量带来不少上市公司逐渐扭亏、海外BD加速等因素。展望下半年我们认为医药行业的估值修复没有结束，创新药有望继续表现但可能不再是唯一主线，细分行业可能是百花齐放的，有创新管线的中药、原料药等传统药企估值也有提升的机会，底部的医疗器械个股如果三季度业绩如期修复也将有望跟上指数的趋势。","fund":{"_id":3000000011383,"__csrcFundId":8785,"stockCode":"011383","shortName":"富安达医药创新混合(011383)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"lastUpdated":"2026-04-30T22:47:34.569Z","status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","managers":[{"stockCode":"db20077904","stockType":"fund_manager","exchange":"fm","tickerId":121906158610,"name":"李守峰"}]},"announcement":{"linkText":"富安达医药创新混合型证券投资基金2025年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1342251","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aece787fea5b3eb04ebcbe","date":"2025-03-30T16:00:00.000Z","stockId":3000000011383,"sao":"2025年一季度A股整体波动较小，上证指数下跌0.48%，深证成指上涨0.86%，创业板指数下跌1.77%；汽车、机械设备、有色等板块涨幅较大，煤炭、石油石化、非银、商贸零售等板块跌幅较多。本基金主要配置在医药行业，一季度中证医药指数表现较为平淡，整体上涨0.94%，但有一些结构性的投资机会，创新药和AI医疗表现较为突出，我们对部分创新药标的进行了波段操作，考虑到特朗普上任以后的不确定性，我们当前主要持有两个方向：一是与财政政策相关度最大的医疗设备行业，医院的需求只会延续不会消失，2025年或有业绩弹性；另一方面就是业绩有一定持续性的部分中药，全年维度我们仍然关注创新药和AI医疗，但前期涨幅较大，需要等待调整下来的投资机会。","declarationDate":"2025-04-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:43:20.404Z","fund":{"_id":3000000011383,"__csrcFundId":8785,"stockCode":"011383","shortName":"富安达医药创新混合(011383)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"lastUpdated":"2026-04-30T22:47:34.569Z","status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","managers":[{"stockCode":"db20077904","stockType":"fund_manager","exchange":"fm","tickerId":121906158610,"name":"李守峰"}]},"announcement":{"linkText":"富安达医药创新混合型证券投资基金2025年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1268799","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aece787fea5b3eb04ebcbd","date":"2024-12-30T16:00:00.000Z","stockId":3000000011383,"sao":"2024年市场整体波动较大，1-9月市场整体跌幅较大，9月中下旬政策密集出台，特别是中央政治局会议传递出稳经济、努力提振资本市场等信号，市场预期瞬时逆转，全年上证指数上涨12.67%，深证成指上涨9.34%，创业板指数上涨13.23%，科创50指数上涨16.07%；分行业看，银行、非银、通信、电子等板块涨幅较大，医药生物、农林牧渔、美容护理、食品饮料等偏消费的板块跌幅较大。本基金主要配置在医药行业，全年中证医疗下跌17.16%，回头看我们在年初低估了多项政策对行业的影响，操作上看，一二季度配置了高分红的中药、医药流通等防御性的板块，三、四季度主要配置了有一定进攻性的创新药和医疗器械设备。","declarationDate":"2025-01-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:43:20.401Z","mo":"2021年医药行业见顶以来，中证医疗指数2021-2024年已经连续四年下跌，我们认为2025年依然延续的概率较小，虽然集采降价、医保控费等政策仍将对行业产生影响，但部分细分行业的估值水平反映了市场的悲观预期，部分个股或将有望在低基数下实现恢复性增长，符合上述条件的板块主要是医疗设备板块，同时有临床进展、新进医保有放量预期的创新药、业绩稳定增长的部分中药，我们也将密切跟踪。","fund":{"_id":3000000011383,"__csrcFundId":8785,"stockCode":"011383","shortName":"富安达医药创新混合(011383)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"lastUpdated":"2026-04-30T22:47:34.569Z","status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","managers":[{"stockCode":"db20077904","stockType":"fund_manager","exchange":"fm","tickerId":121906158610,"name":"李守峰"}]},"announcement":{"linkText":"富安达医药创新混合型证券投资基金2024年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1247032","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aece787fea5b3eb04ebcbc","date":"2024-09-29T16:00:00.000Z","stockId":3000000011383,"sao":"2024年三季度国内经济仍面临有效需求不足的问题，但季末中央政治局及央行公布多项利好政策，市场预期扭转带动A股触底反弹，上证指数上涨12.44%，深证成指上涨19.0%，创业板指数上涨29.21%；行业间分化加大，非银、计算机、电力设备、电子、地产等板块的涨幅都在20%以上，上半年表现较好的煤炭、公用事业、石油石化等板块小幅下跌。本基金主要配置在医药创新相关行业，三季度中证医疗指数上涨22.61%，针对医药的行业治理并没有如预期的结束，药品比价、安徽中成药集采目录中纳入OTC品种等因素仍会带动相关细分行业调整，整体看政策面仍然是存在不确定性的，但部分细分行业的估值水平也反映了政策的预期，我们主要配置在集采出清的行业，如集采过的骨科、仿制药（有创新药催化）以及创新药。","declarationDate":"2024-10-23T16:00:00.000Z","lastUpdated":"2026-03-09T13:43:20.399Z","fund":{"_id":3000000011383,"__csrcFundId":8785,"stockCode":"011383","shortName":"富安达医药创新混合(011383)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"lastUpdated":"2026-04-30T22:47:34.569Z","status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","managers":[{"stockCode":"db20077904","stockType":"fund_manager","exchange":"fm","tickerId":121906158610,"name":"李守峰"}]},"announcement":{"linkText":"富安达医药创新混合型证券投资基金2024年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1170057","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aece787fea5b3eb04ebcbb","date":"2024-06-29T16:00:00.000Z","stockId":3000000011383,"sao":"2024年上半年A股维持震荡格局，上证指数下跌0.25%，深证成指下跌7.1%，创业板指数下跌10.99%；行业间分化较大，银行、煤炭、石油石化、家电、公用事业、有色等板块有一定涨幅，消费者服务、计算机、传媒、医药、地产等行业跌幅较大。本基金主要配置在医药行业，上半年中证医疗指数下跌21.09%，延续了去年的下跌，结构上前期相对比较抗跌的中药和药店等细分板块也有不同程度的下跌。经过回顾反思，我们认为在监管对行业规范化的决心以及政策变化对上市公司业绩的影响等方面的评估有不足，基金净值跟随行业调整。","declarationDate":"2024-07-17T16:00:00.000Z","lastUpdated":"2026-03-09T13:43:20.396Z","mo":"展望下半年，我们将更重视行业监管政策研究，仓位上将更加灵活，考虑到部分上市公司受行业监管政策变化影响导致业绩受到影响，下半年有望在低基数效应下实现较好增长，可能带来行业的反弹。结构上我们相对更看好受行业政策影响相对较小的创新医疗器械、医药商业和院外中成药，关注政策面相对友好的创新药配置机会。","fund":{"_id":3000000011383,"__csrcFundId":8785,"stockCode":"011383","shortName":"富安达医药创新混合(011383)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"lastUpdated":"2026-04-30T22:47:34.569Z","status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","managers":[{"stockCode":"db20077904","stockType":"fund_manager","exchange":"fm","tickerId":121906158610,"name":"李守峰"}]},"announcement":{"linkText":"富安达医药创新混合型证券投资基金2024年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1142449","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aece787fea5b3eb04ebcba","date":"2024-03-30T16:00:00.000Z","stockId":3000000011383,"sao":"2024年一季度A股先抑后扬，上证指数上涨2.23%，深证成指下跌1.3%，创业板指数下跌3.87%；行业间分化加大，家电、有色、煤炭、石油石化等板块涨幅较大，计算机、电子、医药、地产等行业跌幅较大。本基金主要配置在医药行业中创新相关的细分行业，受行业监管政策的变化影响，医药延续调整，中成药、医药商业等板块有一定的相对收益，医疗器械、医疗服务、生物制品等板块跌幅较大。我们认为与2018年医药行业受到“带量采购”冲击不同，医药行业已经经过接近三年的调整，当前行业的估值处于低位，医疗反腐中长期有利于净化行业环境，有明确治疗效果和符合药物经济学的产品反倒是受益的，当前我们仍看好医药行业的发展前景。一季度我们进一步降低了受海外政策影响的医药外包行业配置，主要配置在受行业政策影响相对较小的创新医疗器械、医药商业和中成药，同时增加了政策面相对友好的创新药配置比例。","declarationDate":"2024-04-17T16:00:00.000Z","lastUpdated":"2026-03-09T13:43:20.394Z","fund":{"_id":3000000011383,"__csrcFundId":8785,"stockCode":"011383","shortName":"富安达医药创新混合(011383)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"lastUpdated":"2026-04-30T22:47:34.569Z","status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","managers":[{"stockCode":"db20077904","stockType":"fund_manager","exchange":"fm","tickerId":121906158610,"name":"李守峰"}]},"announcement":{"linkText":"富安达医药创新混合型证券投资基金2024年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1064598","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aece787fea5b3eb04ebcb9","date":"2023-12-30T16:00:00.000Z","stockId":3000000011383,"sao":"2023年疫后复苏低于市场预期，A股延续调整，全年上证指数下跌3.7%，深证成指下跌13.54%，沪深300指数下跌11.38%；板块间分化较大，通信、传媒、煤炭、家电、计算机等板块有一定上涨，消费者服务、地产、建材、电力设备新能源等板块跌幅较大。本基金主要配置在医药创新相关行业，受医药反腐等行业政策影响，医药延续调整，中成药和化学制药板块有一定的正收益，医疗器械、生物制品、医药商业、医疗服务等板块有所调整。我们全年维持了较低的医药外包行业配置，主要配置在受行业政策影响相对较小的创新医疗器械、医药商业和中成药等。","declarationDate":"2024-01-18T16:00:00.000Z","lastUpdated":"2026-03-09T13:43:20.391Z","mo":"我们认为与2018年医药行业受到“带量采购”冲击不同，医药行业已经经过接近三年的调整，当前行业的估值处于低位，医疗反腐中长期有利于净化行业环境，有明确治疗效果和符合药物经济学的产品反倒是受益的，当前我们仍看好医药行业的发展前景。","fund":{"_id":3000000011383,"__csrcFundId":8785,"stockCode":"011383","shortName":"富安达医药创新混合(011383)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"lastUpdated":"2026-04-30T22:47:34.569Z","status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","managers":[{"stockCode":"db20077904","stockType":"fund_manager","exchange":"fm","tickerId":121906158610,"name":"李守峰"}]},"announcement":{"linkText":"富安达医药创新混合型证券投资基金2023年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1055591","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aece787fea5b3eb04ebcb8","date":"2023-09-29T16:00:00.000Z","stockId":3000000011383,"sao":"2023年三季度A股延续调整，单季度上证指数下跌2.86%，深证成指下跌8.32%，沪深300指数下跌3.98%；板块轮动加速，周期类行业如煤炭、非银、石化、地产等板块有一定上涨，上半年表现较好的传媒、计算机、电子等板块跌幅较大。本基金主要配置在医药行业中创新相关的细分行业，三季度受医疗反腐事件的影响，单季度申万医药生物指数下跌1.57%，内部仍然分化，医疗服务、化学制剂板块上涨，其它细分行业如医药商业、医疗器械、中药等板块跌幅较大。在持仓结构上我们有所调整，减持了血制品、中药等细分板块的配置，增加了创新医疗器械、创新药的配置，对于医药行业的中长期走势我们是较为乐观的，与2018年医药行业受到“带量采购”冲击不同，当前行业的估值处于低位，医疗反腐中长期有利于净化行业环境，有明确治疗效果和符合药物经济学的产品反倒是受益的。","declarationDate":"2023-10-23T16:00:00.000Z","lastUpdated":"2026-03-09T13:43:20.389Z","fund":{"_id":3000000011383,"__csrcFundId":8785,"stockCode":"011383","shortName":"富安达医药创新混合(011383)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"lastUpdated":"2026-04-30T22:47:34.569Z","status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","managers":[{"stockCode":"db20077904","stockType":"fund_manager","exchange":"fm","tickerId":121906158610,"name":"李守峰"}]},"announcement":{"linkText":"富安达医药创新混合型证券投资基金2023年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=985351","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aece787fea5b3eb04ebcb7","date":"2023-06-29T16:00:00.000Z","stockId":3000000011383,"sao":"2023年上半年主要股指涨跌不一，上证指数上涨3.65%，深证成指上涨0.1%，创业板指下跌5.61 %；行业间分化较大，通信、传媒、计算机、电子等板块涨幅较大，商贸零售、美容护理、地产、电力设备、食品饮料等板块有一定下跌。本基金主要配置在医药创新相关行业，申万医药生物指数上半年下跌5.56%，不同细分行业表现差异较大，血制品、中药、医药商业等板块上涨，其它细分行业如医疗服务、医疗器械、CXO等板块跌幅较大，下跌的板块均是2019-2021年医药牛市中的领涨板块。上半年我们立足业绩主线，增持了二季度业绩持续性较好的部分中药标的，与诊疗复苏相关的血液制品、麻醉药等细分行业标的以及有望兑现产品管线的创新药标的。","declarationDate":"2023-07-19T16:00:00.000Z","lastUpdated":"2026-03-09T13:43:20.386Z","mo":"我们认为经过两年多的调整，医药行业的估值已经处于历史低位，创新药的政策支持力度也在边际向上，部分细分行业如仿制药、器械集采政策的影响已经出清，我们看好医药行业2023年下半年的表现，下半年我们将努力寻找医药行业创新相关的结构性机会。","fund":{"_id":3000000011383,"__csrcFundId":8785,"stockCode":"011383","shortName":"富安达医药创新混合(011383)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"lastUpdated":"2026-04-30T22:47:34.569Z","status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","managers":[{"stockCode":"db20077904","stockType":"fund_manager","exchange":"fm","tickerId":121906158610,"name":"李守峰"}]},"announcement":{"linkText":"富安达医药创新混合型证券投资基金2023年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=955693","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aece787fea5b3eb04ebcb6","date":"2023-03-30T16:00:00.000Z","stockId":3000000011383,"sao":"一季度A股整体延续反弹，单季度上证指数上涨5.94%，深证成指上涨6.45%，沪深300指数上涨4.63%；行业间分化较大，计算机、通讯、传媒、电子等板块涨幅较大，商贸零售、地产、电力设备、银行等板块有一定下跌。本基金主要配置在医药行业中与创新相关的细分子行业，申万医药指数一季度上涨1.86%，但医药内部分化也比较大，中药、医药商业等板块上涨，其它细分行业如医疗服务、医疗器械、CXO等板块跌幅较大，下跌的板块均是2019-2021年医药牛市中的领涨板块。我们认为上轮医药牛市上涨的医药白马股虽然估值已经较为便宜，但一些细分行业出现了竞争格局恶化的情况，仍需等待基本面反转，在此基础上一季度我们对持仓做了一定调整，增持了政策面友好且一季度业绩预期较好的中药板块及部分政策免疫的医疗器械，降低了高值耗材、药店等板块的配置。","declarationDate":"2023-04-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:43:20.384Z","fund":{"_id":3000000011383,"__csrcFundId":8785,"stockCode":"011383","shortName":"富安达医药创新混合(011383)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"lastUpdated":"2026-04-30T22:47:34.569Z","status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","managers":[{"stockCode":"db20077904","stockType":"fund_manager","exchange":"fm","tickerId":121906158610,"name":"李守峰"}]},"announcement":{"linkText":"富安达医药创新混合型证券投资基金2023年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=882982","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aece787fea5b3eb04ebcb5","date":"2022-12-30T16:00:00.000Z","stockId":3000000011383,"sao":"2022年A股受到整体盈利下行以及俄乌冲突、美联储加息、疫情超预期扩散等因素导致的估值下行影响大幅下跌，全年上证指数下跌15.13%，深证成指下跌25.85%，创业板指数下跌29.37%。本基金主要配置在医药行业，申万医药指数连续两年下跌，2022年全年下跌20.34%。我们在2022年下半年配置方向上有所调整，降低了拥挤度较高的CXO、医疗服务等板块的配置比例，主要加配了两条主线，一个是仿制药板块，主要是仿制药板块的盈利已经开始触底回升，同时部分公司第二增长曲线已经有了一定的体量；另一个主线是政策面比较友好的医疗器械、设备相关公司。","declarationDate":"2023-01-19T16:00:00.000Z","lastUpdated":"2026-03-09T13:43:20.381Z","mo":"我们认为医药行业已经调整了两年，估值已经处于历史低位，部分细分行业如仿制药集采政策的影响已经出清，我们看好医药行业2023年的表现，行业及个股的投资机会预计多于去年。新的一年我们将努力寻找医药行业里面的结构性机会，力争为投资者贡献长期稳健回报。","fund":{"_id":3000000011383,"__csrcFundId":8785,"stockCode":"011383","shortName":"富安达医药创新混合(011383)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"lastUpdated":"2026-04-30T22:47:34.569Z","status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","managers":[{"stockCode":"db20077904","stockType":"fund_manager","exchange":"fm","tickerId":121906158610,"name":"李守峰"}]},"announcement":{"linkText":"富安达医药创新混合型证券投资基金2022年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=865540","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aece787fea5b3eb04ebcb4","date":"2022-09-29T16:00:00.000Z","stockId":3000000011383,"sao":"三季度受到美联储加息进度超预期以及俄乌冲突升级等因素的影响，A股整体调整幅度较大，第三季度上证指数下跌11.01%，深证成指下跌16.42%，沪深300指数下跌15.16%，已经接近4月份的低点；分行业看，除了煤炭板块有所上涨以外，其它行业均下跌。本基金主要配置在医药行业上，申万医药指数延续了去年7月开始的调整，三季度下跌15.98%，医药行业依然处在调整中。从医药行业的历史复盘来看，每一轮领涨的板块和个股均有所不同，我们认为主要原因还是上一轮领涨的细分行业逻辑演绎的较为充分，同时面临景气度下行的风险，因此在新一轮的医药行情中较难创出新高，因此我们选择配置了一些没有被充分挖掘的细分行业和个股，主要包括政策面已经出清、有望重新迎来业绩增长周期的仿制药、同样逻辑的还有骨科高值耗材，受集采政策影响较小的创新医疗器械等。","declarationDate":"2022-10-24T16:00:00.000Z","lastUpdated":"2026-03-09T13:43:20.379Z","fund":{"_id":3000000011383,"__csrcFundId":8785,"stockCode":"011383","shortName":"富安达医药创新混合(011383)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"lastUpdated":"2026-04-30T22:47:34.569Z","status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","managers":[{"stockCode":"db20077904","stockType":"fund_manager","exchange":"fm","tickerId":121906158610,"name":"李守峰"}]},"announcement":{"linkText":"富安达医药创新混合型证券投资基金2022年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=803408","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aece787fea5b3eb04ebcb3","date":"2022-06-29T16:00:00.000Z","stockId":3000000011383,"sao":"2022年上半年A股探底回升，上证指数下跌6.63%，深证成指下跌13.2%，沪深300下跌9.22%，中小100下跌11.56%；分行业看，煤炭、建筑、石化等细分行业涨幅居前，计算机、电子、传媒等板块下跌幅度较大。医药板块延续了去年下半年开始的下跌，申万医药生物指数上半年下跌14.24%。本基金主要配置在医药创新相关的CXO、医疗设备、创新医疗器械、生命科学上游、创新中药等细分子行业的相关上市公司。","declarationDate":"2022-07-19T16:00:00.000Z","lastUpdated":"2026-03-09T13:43:20.376Z","mo":"展望下半年，尽管还可能有波折，我们看好医药长期的表现，经过一年多的调整，医药板块的估值已经基本接近2012年年初和2018年年底两次医药板块底部的估值，我们认为继续下跌的空间相对较小；另外，部分细分板块如CXO、医疗器械设备、中药等龙头公司的业绩或将仍然保持较快增长。","fund":{"_id":3000000011383,"__csrcFundId":8785,"stockCode":"011383","shortName":"富安达医药创新混合(011383)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"lastUpdated":"2026-04-30T22:47:34.569Z","status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","managers":[{"stockCode":"db20077904","stockType":"fund_manager","exchange":"fm","tickerId":121906158610,"name":"李守峰"}]},"announcement":{"linkText":"富安达医药创新混合型证券投资基金2022年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=779072","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aece787fea5b3eb04ebcb2","date":"2022-03-30T16:00:00.000Z","stockId":3000000011383,"sao":"2022年一季度A股受到国内经济增长压力、新冠疫情散发、海外流动性收紧、俄乌冲突等诸多因素的影响，整体下跌幅度较大，上证指数下跌10.65%，深证成指下跌18.44%，创业板指数下跌19.96%。行业间分化较大，煤炭、地产、银行、建筑等顺周期行业仍有一定涨幅，电子、汽车、军工、新能源等成长类板块跌幅较大。本基金重仓配置在医药行业中具有创新性的公司，出于对行业景气度可能下行的担忧，我们减仓了中小市值的临床外包公司，仅保留了抗风险能力更强的龙头公司，增加了对中药、估值与增长匹配的医疗器械/医疗设备类、为创新提供支持的生命科学上游公司的配置。","declarationDate":"2022-04-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:43:20.374Z","fund":{"_id":3000000011383,"__csrcFundId":8785,"stockCode":"011383","shortName":"富安达医药创新混合(011383)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"lastUpdated":"2026-04-30T22:47:34.569Z","status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","managers":[{"stockCode":"db20077904","stockType":"fund_manager","exchange":"fm","tickerId":121906158610,"name":"李守峰"}]},"announcement":{"linkText":"富安达医药创新混合型证券投资基金2022年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=722566","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aece787fea5b3eb04ebcb1","date":"2021-12-30T16:00:00.000Z","stockId":3000000011383,"sao":"2021年A股整体小幅上涨，上证指数上涨4.8%，深证成指上涨2.67%，创业板指数上涨12.02%。行业间分化较大，有色、化工、电力设备新能源、钢铁、公用事业等行业涨幅居前，休闲服务、农林牧渔、医药等板块下跌。本基金成立于2021年3月9日，全年净值下跌5.91%，小幅跑赢申万医药指数。本基金重仓配置在医药行业创新相关的标的上，下半年以来医药行业遇到了一些政策利空，诸如\"抗肿瘤药临床应用管理办法\"、\"安徽省的化学发光试剂集采\"、\"教育双减政策出台后市场担心医药也会强监管\"等，医药行业指数见顶回落后大幅下跌，本基金的重仓股如CDMO龙头、CRO龙头、医疗器械龙头、电生理医疗器械的特色上市公司、眼科龙头等均出现了一定的下跌。除了政策原因外，这些公司的业绩三季度也略低于市场预期，叠加估值处于历史高位等综合因素造成股价的大幅下跌。","declarationDate":"2022-01-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:43:20.371Z","mo":"2022年，我们认为国内经济下行压力较大，货币及财政政策有一定的宽松空间，而海外市场如美国因通胀压力加大而进入加息周期，A股低估值股票相对较为安全，成长股则需要观察何时国内经济能够企稳回升。具体到医药行业，2018年以来治理行业的\"注册端+定价端\"的政策接踵出台，未来也将在\"支付端\"进行政策试点，市场因此对医药行业的预期不太乐观，甚至认为行业或将变成类公用事业，我们认为从《 \"十四五\"医药工业发展规划》来看，医药行业仍然是成长性的行业，十四五期间对创新性、产业链自主可控、国际化提出了更高的要求，相关政策的出台将引领行业更高质量发展，也将带来结构性的投资机会。","fund":{"_id":3000000011383,"__csrcFundId":8785,"stockCode":"011383","shortName":"富安达医药创新混合(011383)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"lastUpdated":"2026-04-30T22:47:34.569Z","status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","managers":[{"stockCode":"db20077904","stockType":"fund_manager","exchange":"fm","tickerId":121906158610,"name":"李守峰"}]},"announcement":{"linkText":"富安达医药创新混合型证券投资基金2021年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=708381","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aece787fea5b3eb04ebcb0","date":"2021-09-29T16:00:00.000Z","stockId":3000000011383,"sao":"2021年三季度A股见顶回落，上证指数下跌0.64%，深证成指下跌1.21%，创业板指数下跌6.69%；行业分化较大，周期类板块有色、采掘、公用事业、化工等行业涨幅居前，休闲服务、食品饮料、医药等板块下跌幅度较大。我们主要配置在医药行业中创新相关的细分子行业，医药行业整体三季度跌幅都较大，主要是因为受到了肿瘤药临床指导原则、省级的化学发光带量采购以等政策的影响，本基金净值出现了一定的回撤；展望后市我们认为医药行业的行情仍然是结构性的，经过2019至2020年两年的大幅上涨，一些公认的好标的估值已经处于历史高位，需要时间去消化估值，未来的超额收益有可能来自于行业中之前关注不是那么充分的标的；医药行业近几年受政策影响结构变化较大，唯有创新才能穿越行业的周期，后续我们将挖掘医药创新中的alpha，力争为投资者贡献稳健收益。","declarationDate":"2021-10-25T16:00:00.000Z","lastUpdated":"2026-03-09T13:43:20.369Z","fund":{"_id":3000000011383,"__csrcFundId":8785,"stockCode":"011383","shortName":"富安达医药创新混合(011383)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"lastUpdated":"2026-04-30T22:47:34.569Z","status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","managers":[{"stockCode":"db20077904","stockType":"fund_manager","exchange":"fm","tickerId":121906158610,"name":"李守峰"}]},"announcement":{"linkText":"富安达医药创新混合型证券投资基金2021年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=651345","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aece787fea5b3eb04ebcaf","date":"2021-06-29T16:00:00.000Z","stockId":3000000011383,"sao":"2021年上半年A股先是冲高回落，在经历了核心资产大幅下跌后有所反弹。总体来看，上证指数上涨3.4%，深证成指上涨4.78%，创业板指数上涨17.22%；行业方面分化较为明显，钢铁、煤炭、电力设备涨幅较大，非银、家电、军工等行业跌幅较大。我们在4月份开始逐步建仓，重点配置在与医药创新相关的标的，结构上我们主要配置了景气度高的CXO、医疗器械、服务等细分行业的龙头上市公司。申万医药指数上半年上涨9.33%，大幅跑赢沪深300指数，我们的基金也跑赢了申万医药指数，总体来看我们上半年小幅跑赢了业绩比较基准。","declarationDate":"2021-07-19T16:00:00.000Z","lastUpdated":"2026-03-09T13:43:20.366Z","mo":"我们重仓配置在与医药创新相关的行业，今年以来医药行业受政策面影响波动较大，部分核心资产有一定下跌。我们认为不必对医药行业后续走势过分担忧，医药行业整体估值水平并不高，尤其是一些增长较好的二线资产；只有部分核心资产估值水平较高需要时间来消化，。后续我们将挖掘增长和估值匹配度较高的二线资产，力争为投资者贡献稳健收益。","fund":{"_id":3000000011383,"__csrcFundId":8785,"stockCode":"011383","shortName":"富安达医药创新混合(011383)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":11383,"masterFundFlag":1,"lastUpdated":"2026-04-30T22:47:34.569Z","status":"normal","name":"富安达医药创新混合型证券投资基金","exchange":"jj","followedNum":7,"inceptionDate":"2021-03-08T16:00:00.000Z","fundCollectionId":4000050650000,"currency":"CNY","masterFundShortName":"富安达医药创新混合","setUpDate":"2021-03-08T16:00:00.000Z","setUpAssetScale":574342121.44,"setUpShares":574342121.44,"pinyin":"fadyycxhhxzqtzjj","managers":[{"stockCode":"db20077904","stockType":"fund_manager","exchange":"fm","tickerId":121906158610,"name":"李守峰"}]},"announcement":{"linkText":"富安达医药创新混合型证券投资基金2021年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=634233","linkType":"PDF","source":"csrc_pdf"}}]}